Lipid Nanovesicles in Cancer Treatment: Improving Targeting and Stability of Antisense Oligonucleotides

被引：0
作者：
Ding, Hui-yan [1 ,3 ]
Zhou, Han [4 ,5 ]
Jiang, Yi [1 ,2 ]
Chen, Si-si [6 ]
Wu, Xiao-xia [1 ,2 ]
Li, Yang [1 ,2 ]
Luo, Jun [1 ,2 ]
Zhang, Peng-fei [7 ]
Ding, Yi-nan [1 ,2 ]
机构：
[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Intervent Radiol,Zhejiang Key Lab Imaging & I, Hangzhou 310022, Zhejiang, Peoples R China
[2] Zhejiang Canc Hosp, Zhejiang Prov Res Ctr Innovat Technol & Equipment, Hangzhou 310022, Peoples R China
[3] Univ Macau, Fac Hlth Sci, Dept Biomed Sci, Taipa 999078, Macao, Peoples R China
[4] Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Sch Mol Med, Hangzhou 310022, Zhejiang, Peoples R China
[5] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
[6] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Hangzhou 310022, Zhejiang, Peoples R China
[7] Inner Mongolia Univ, Inst Biomed Sci, Hohhot 010020, Inner Mongolia, Peoples R China
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2025年 / 19卷
基金：
中国博士后科学基金; 中国国家自然科学基金;
关键词：
cancer therapy; antisense oligonucleotides; lipid nanovesicles; liposomes; extracellular vesicles; cell membrane vesicles; EXTRACELLULAR VESICLES; THERAPEUTIC DELIVERY; MEDIATED DELIVERY; DOWN-REGULATION; NANOPARTICLES; CELLS; SIRNA; SUPPRESSION; PHARMACOLOGY; RESISTANCE;
D O I：
10.2147/DDDT.S507402
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Cancer remains a leading cause of mortality worldwide, accounting for approximately 10 million deaths annually. Standard treatments, including surgery, radiotherapy, and chemotherapy, often result in damage to healthy cells and severe toxic side effects. In recent years, antisense technology therapeutics, which interfere with RNA translation through complementary base pairing, have emerged as promising approaches for cancer treatment. Despite the availability of various antisense oligonucleotide (ASO) drugs on the market, challenges such as poor active targeting and susceptibility to clearance by circulating enzymes remain. Compared with other delivery systems, lipid nanovesicle (LNV) delivery systems offer a potential solution that uniquely enhances ASO targeting and stability. Studies have shown that LNVs can increase the accumulation of ASOs in tumor sites several-fold, significantly reducing systemic toxic reactions and demonstrating increased therapeutic efficiency in preclinical models. Additionally, LNVs can protect ASOs from enzymatic degradation within the body, extending their half-life and thus enhancing their therapeutic effects. This paper provides a comprehensive review of recent examples and applications of LNV delivery of ASOs in cancer treatment, highlighting their unique functions and outcomes. Furthermore, this paper discusses the key challenges and potential impacts of this innovative approach to cancer therapy.
引用
收藏
页码：1001 / 1023
页数：23
相关论文
共 135 条
  • [1] Sung H, Ferlay J, Siegel RL, Et al., Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries, Ca Cancer J Clin, 71, 3, pp. 209-249, (2021)
  • [2] Kaur R, Bhardwaj A, Gupta S., Cancer treatment therapies: traditional to modern approaches to combat cancers, Mol Biol Rep, 50, 11, pp. 9663-9676, (2023)
  • [3] Zhang C, Zhang B., RNA therapeutics: updates and future potential, Sci China Life Sci, 66, 1, pp. 12-30, (2023)
  • [4] Crooke ST, Witztum JL, Bennett CF, Baker BF., RNA-targeted therapeutics, Cell Metab, 29, 2, (2019)
  • [5] Sergeeva O, Akhmetova E, Dukova S, Et al., Structure-activity relationship study of mesyl and busyl phosphoramidate antisense oligonucleo-tides for unaided and PSMA-mediated uptake into prostate cancer cells, Front Chem, 12, (2024)
  • [6] Li Y, Mondaza-Hernandez JL, Moura DS, Et al., Stat6-targeting antisense oligonucleotides against solitary fibrous tumor, Mol Ther Nucleic Acids, 35, 2, (2024)
  • [7] Grabowska-Pyrzewicz W, Want A, Leszek J, Wojda U., Antisense oligonucleotides for Alzheimer’s disease therapy: from the mRNA to miRNA paradigm, Ebiomedicine, 74, (2021)
  • [8] Chen S, Sbuh N, Veedu RN., Antisense oligonucleotides as potential therapeutics for type 2 diabetes, Nucleic Acid Ther, 31, 1, pp. 39-57, (2021)
  • [9] Bennett CF., Therapeutic antisense oligonucleotides are coming of age, Annu Rev Med, 70, pp. 307-321, (2019)
  • [10] Lai F, Damle SS, Ling KK, Rigo F., Directed RNase H cleavage of nascent transcripts causes transcription termination, Mol Cell, 77, 5, pp. 1032-1043, (2020)
12345678910